Biomaterial Database

Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion. 1999

J Berman, and R Dietze

Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA.

Amphotericin B is an effective antileishmanial agent whose use is limited by drug toxicity. The development of less toxic, lipid encapsulated formulations of amphotericin B as antimycotic agents has made these formulations available for testing against visceral leishmaniasis, a disease ideally suited for 'liposomal' therapy since the parasites are only found within reticuloendothelial macrophages. In phase II experiments of Amphotericin B Colloidal Dispersion (ABCD) for Brazilian kala-azar, 10 of 10 patients were cured with 2 mg/kg/day for 10 days; 9 of 9 patients were cured with 2 mg/kg/day for 7 days; 9 of 10 patients were cured with 2 mg/kg/day for 5 days. The ability to cure 90% of kala-azar patients with a regimen of merely 5 days is remarkable considering that 20-40 days of treatment with pentavalent antimonials and a 28-40 day course of (every-other-day) amphotericin B desoxycholate therapy are otherwise needed. Although ABCD did frequently cause a syndrome of fever and respiratory distress during infusion for children less than 6 years of age, the virtual absence of kidney toxicity was striking.

UI	MeSH Term	Description	Entries
D007223	Infant	A child between 1 and 23 months of age.	Infants
D007898	Leishmaniasis, Visceral	A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	Black Fever,Kala-Azar,Fever, Black,Kala Azar,Visceral Leishmaniasis
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D002675	Child, Preschool	A child between the ages of 2 and 5.	Children, Preschool,Preschool Child,Preschool Children
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666	Amphotericin B	Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.	Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000981	Antiprotozoal Agents	Substances that are destructive to protozoans.	Schizonticides,Agents, Antiprotozoal
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017322	Clinical Trials, Phase II as Topic	Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.	Drug Evaluation, FDA Phase 2 as Topic,Drug Evaluation, FDA Phase II as Topic,Evaluation Studies, FDA Phase 2 as Topic,Evaluation Studies, FDA Phase II as Topic